She’s a Barbie girl. Aaliyah has joined the hallowed halls of legendary singers immortalized in Barbie form by doll maker Mattel. The collectible Barbie, which celebrates the artist’s enduring ...

(AP Photo/Jim Cooper, File) (Jim Cooper, AP2001) A new Barbie doll was released Thursday to honor the late Detroit-raised R&B singer Aaliyah on what would have been her 46th birthday. The doll ...

More than twenty years after her untimely passing, the Princess of R&B continues to hold a sturdy stake in the culture. In collaboration with Aaliyah's brother Rashad Haughton, Mattel is releasing ...

Preorders for the dolls, which go on sale Jan. 26, have already sold out. By Mia Galuppo Film Writer If you purchase an independently reviewed product or service through a link on our website ...

Barbie's latest launch honors the life and legacy of Aaliyah. Barbie is paying homage to one of the most iconic voices of the 1990s, Aaliyah, with the launch of a collectible doll in her honor.

The collector series doll pays homage to the late singer's iconic '90s style. By Kyle Hodge All products and services featured are independently chosen by editors. However, Billboard may receive a ...

Caren Marsh Doll survived a plane crash that killed 35 people in 1949—and that’s not even the most interesting thing about her. Initially, she was told by a doctor that her foot would have to ...

Madrigal Pharmaceuticals announced its preliminary Q4 and full-year results. The company topped the official Wall Street estimates, but seems to have missed the so-called "whisper numbers ...

CONSHOHOCKEN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were sinking 13.3% lower as of 11:11 a.m. ET on Monday. The sell-off came after the drugmaker announced its preliminary fourth-quarter and full ...

Rezdiffra's strong launch has been confirmed by robust sales in the first two quarters, even though it may have only been used in 2% of its current target patient population. Competitors with MASH ...